BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 94.1% in January

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 94,800 shares, a decline of 94.1% from the January 15th total of 1,620,000 shares. Currently, 2.8% of the shares of the stock are short sold. Based on an average trading volume of 346,800 shares, the short-interest ratio is currently 0.3 days.

BriaCell Therapeutics Price Performance

Shares of BCTX stock traded up $0.35 during mid-day trading on Wednesday, hitting $3.78. The company had a trading volume of 257,061 shares, compared to its average volume of 664,727. The stock’s 50 day moving average price is $7.86 and its 200-day moving average price is $10.11. BriaCell Therapeutics has a 52-week low of $3.33 and a 52-week high of $56.70. The company has a market capitalization of $11.15 million, a P/E ratio of -0.28 and a beta of 1.59.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($1.20) by ($2.10). On average, equities research analysts expect that BriaCell Therapeutics will post -2.45 earnings per share for the current year.

Institutional Investors Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Virtu Financial LLC bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 48,663 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.65% of BriaCell Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 15.42% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright increased their target price on BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.